Importantly, sPD-L1 and exoPD-L1 have been recognized as biomarkers to predict the efficacy of immunotherapy in melanoma [23–27], non-small cell lung cancer (NSCLC) [28] and renal cell carcinoma (RCC) [25]. Here, SPDL1 is linked to renal cell carcinoma.